Terms: = Prostate cancer AND KLK2, P20151, 3817, ENSG00000167751, MGC12201, hK2, KLK2A2 AND Staging
15 results:
1. KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy.
Lunger L; Retz M; Bandur M; Souchay M; Vitzthum E; Jäger M; Weirich G; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Koll F; Gschwend JE; Nawroth R; Heck MM
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):362-369. PubMed ID: 32978525
[TBL] [Abstract] [Full Text] [Related]
2. Tumor markers in prostate cancer I: blood-based markers.
Shariat SF; Semjonow A; Lilja H; Savage C; Vickers AJ; Bjartell A
Acta Oncol; 2011 Jun; 50 Suppl 1(Suppl 1):61-75. PubMed ID: 21604943
[TBL] [Abstract] [Full Text] [Related]
3. Screening for prostate cancer: an update.
Shariat SF; Scardino PT; Lilja H
Can J Urol; 2008 Dec; 15(6):4363-74. PubMed ID: 19046489
[TBL] [Abstract] [Full Text] [Related]
4. [PSA and hk2 in the diagnosis of prostate cancer].
Alapont Alacreu JM; Navarro Rosales S; Budía Alba A; España Furió F; Morera Martínez F; Jiménez Cruz JF
Actas Urol Esp; 2008 Jun; 32(6):575-88. PubMed ID: 18655340
[TBL] [Abstract] [Full Text] [Related]
5. Serum human glandular kallikrein 2 (hk2) for distinguishing stage and grade of prostate cancer.
Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
[TBL] [Abstract] [Full Text] [Related]
7. [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].
Haese A; Graefen M; Palisaar J; Huland E; Huland H
Urologe A; 2003 Sep; 42(9):1172-87. PubMed ID: 14504750
[TBL] [Abstract] [Full Text] [Related]
8. Multiple tumor marker analyses (PSA, hk2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR.
Fuessel S; Sickert D; Meye A; Klenk U; Schmidt U; Schmitz M; Rost AK; Weigle B; Kiessling A; Wirth MP
Int J Oncol; 2003 Jul; 23(1):221-8. PubMed ID: 12792797
[TBL] [Abstract] [Full Text] [Related]
9. Standardization of two immunoassays for human glandular kallikrein 2.
Haese A; Vaisanen V; Finlay JA; Pettersson K; Rittenhouse HG; Partin AW; Bruzek DJ; Sokoll LJ; Lilja H; Chan DW
Clin Chem; 2003 Apr; 49(4):601-10. PubMed ID: 12651813
[TBL] [Abstract] [Full Text] [Related]
10. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
[TBL] [Abstract] [Full Text] [Related]
11. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hk2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
Becker C; Noldus J; Diamandis E; Lilja H
Crit Rev Clin Lab Sci; 2001 Oct; 38(5):357-99. PubMed ID: 11720279
[TBL] [Abstract] [Full Text] [Related]
12. Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
Ylikoski A; Karp M; Pettersson K; Lilja H; Lövgren T
J Mol Diagn; 2001 Aug; 3(3):111-22. PubMed ID: 11486050
[TBL] [Abstract] [Full Text] [Related]
13. Blood and serum substances for markers of prostate cancer.
Bangma CH; Verhagen PC
Microsc Res Tech; 2000 Dec; 51(5):430-5. PubMed ID: 11074613
[TBL] [Abstract] [Full Text] [Related]
14. Molecular forms of prostate-specific antigen and human kallikrein 2 (hk2) in urine are not clinically useful for early detection and staging of prostate cancer.
Pannek J; Rittenhouse HG; Evans CL; Finlay JA; Bruzek DJ; Cox JL; Chan DW; Subong EN; Partin AW
Urology; 1997 Nov; 50(5):715-21. PubMed ID: 9372881
[TBL] [Abstract] [Full Text] [Related]
15. prostate-specific antigen: what's new in 1997.
Pannek J; Partin AW
Oncology (Williston Park); 1997 Sep; 11(9):1273-8; discussion 1279-82. PubMed ID: 9306417
[TBL] [Abstract] [Full Text] [Related]
